Search Results - "Foà, R."

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma by Piva, R, Deaglio, S, Famà, R, Buonincontri, R, Scarfò, I, Bruscaggin, A, Mereu, E, Serra, S, Spina, V, Brusa, D, Garaffo, G, Monti, S, Dal Bo, M, Marasca, R, Arcaini, L, Neri, A, Gattei, V, Paulli, M, Tiacci, E, Bertoni, F, Pileri, S A, Foà, R, Inghirami, G, Gaidano, G, Rossi, D

Get full text

Management of CLL in the elderly by Cuneo, A., Foà, R.

Get full text

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma by Morschhauser, F., Marlton, P., Vitolo, U., Lindén, O., Seymour, J.F., Crump, M., Coiffier, B., Foà, R., Wassner, E., Burger, H.-U., Brennan, B., Mendila, M.

“…Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated…”
Get full text

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease by Mauro, F R, Chauvie, S, Paoloni, F, Biggi, A, Cimino, G, Rago, A, Gentile, M, Morabito, F, Coscia, M, Bellò, M, Sacchetti, G M, Rossi, D, Laurenti, L, Autore, F, Campanelli, M, Trastulli, F, Nicolai, E, Riminucci, M, Gaidano, G, Guarini, A, Gallamini, A, Foà, R

“…In order to evaluate the predictive value of positron emission tomography–computed tomography (PET/CT) in discriminating the presence of a Richter’s syndrome…”
Get full text

The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα by Vargas Romero, P, Cialfi, S, Palermo, R, De Blasio, C, Checquolo, S, Bellavia, D, Chiaretti, S, Foà, R, Amadori, A, Gulino, A, Zardo, G, Talora, C, Screpanti, I

Get full text

Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review by Rostagno, E., Campanati, A., Mordini, N., Cannici, C., Cioce, M., De Cecco, V., Samarani, E., Foà, R., Olivieri, A., Botti, S.

“…Skin is usually the first and most affected organ involved in graft‐versus‐host disease (GvHD), and treatment is still a clinical challenge. Although the need…”
Get full text

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial by Cortelezzi, A, Sciumè, M, Liberati, A M, Vincenti, D, Cuneo, A, Reda, G, Laurenti, L, Zaja, F, Marasca, R, Chiarenza, A, Gritti, G, Orsucci, L, Storti, S, Angelucci, E, Cascavilla, N, Gobbi, M, Mauro, F R, Morabito, F, Fabris, S, Piciocchi, A, Vignetti, M, Neri, A, Rossi, D, Giannarelli, D, Guarini, A, Foà, R

“…We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the…”
Get full text

Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre by Santoro, C., Di Mauro, R., Baldacci, E., De Angelis, F., Abbruzzese, R., Barone, F., Bochicchio, R. A., Ferrara, G., Guarini, A., Foà, R., Mazzucconi, M. G.

“…Summary Bleeding phenotype in factor XI (FXI)‐deficient patients is variable, and not related to baseline FXI:Act. Aims of our study were to describe the…”
Get full text

Viral infections associated with the clinical use of monoclonal antibodies by Gentile, G., Foà, R.

“…In recent years, immunomodulatory agents, such as monoclonal antibodies (mAbs), have been effectively utilized in the management of several malignancies, in…”
Get full text

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia by Bernson, E, Hallner, A, Sander, F E, Wilsson, O, Werlenius, O, Rydström, A, Kiffin, R, Brune, M, Foà, R, Aurelius, J, Martner, A, Hellstrand, K, Thorén, F B

“…Interactions between killer-immunoglobulin-like receptors (KIRs) and their HLA class I ligands are instrumental in natural killer (NK) cell regulation and…”
Get full text

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients by Raponi, S., Del Giudice, I., Marinelli, M., Wang, J., Cafforio, L., Ilari, C., Piciocchi, A., Messina, M., Bonina, S., Tavolaro, S., Bordyuh, M., Mariglia, P., Peragine, N., Mauro, F.R., Chiaretti, S., Molica, S., Gentile, M., Visentin, A., Trentin, L., Rigolin, G.M., Cuneo, A., Diop, F., Rossi, D., Gaidano, G., Guarini, A., Rabadan, R., Foà, R.

“…Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase…”
Get full text

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia by Österborg, A, Foà, R, Bezares, R F, Dearden, C, Dyer, M J S, Geisler, C, Lin, T S, Montillo, M, van Oers, M H J, Wendtner, C-M, Rai, K R

“…The consensus views of an expert roundtable meeting are presented as updated management guidelines for using alemtuzumab in chronic lymphocytic leukemia. Since…”
Get full text

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 by Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O G, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A K, Foà, R, Gökbuget, N, Goldstone, A H, Goulden, N, Henze, G, Hoelzer, D, Janka-Schaub, G E, Macintyre, E A, Pieters, R, Rambaldi, A, Ribera, J-M, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, van Dongen, J J M

“…Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia…”
Get full text

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients by Soverini, S, De Benedittis, C, Papayannidis, C, Polakova, K Machova, Venturi, C, Russo, D, Bresciani, P, Iurlo, A, Mancini, M, Vitale, A, Chiaretti, S, Foà, R, Abruzzese, E, Sorà, F, Kohlmann, A, Haferlach, T, Baccarani, M, Cavo, M, Martinelli, G

Get full text

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile by Giudice, I Del, Rigolin, G M, Raponi, S, Cafforio, L, Ilari, C, Wang, J, Bordyuh, M, Piciocchi, A, Marinelli, M, Nanni, M, Tavolaro, S, Filetti, M, Bardi, A, Tammiso, E, Volta, E, Negrini, M, Saccenti, E, Mauro, F R, Rossi, D, Gaidano, G, Guarini, A, Rabadan, R, Cuneo, A, Foà, R

Get full text

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) by Alessandrino, Emilio Paolo, Della Porta, Matteo Giovanni, Bacigalupo, Andrea, Van Lint, Maria Teresa, Falda, Michele, Onida, Francesco, Bernardi, Massimo, Iori, Anna Paola, Rambaldi, Alessandro, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Malcovati, Luca, Pascutto, Cristiana, Oneto, Rosi, Fanin, Renato, Bosi, Alberto

“…We evaluated the impact of World Health Organization (WHO) classification and WHO classification–based Prognostic Scoring System (WPSS) on the outcome of…”
Get full text

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus by Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F.

“…The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about…”
Get full text

A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia by Capria, S., Foà, R., De Giacomo, T., Gentile, G., Micozzi, A., La Rocca, U., Iori, A. P., Trisolini, S. M., Ballotta, L., Guarini, A.

“…The occurrence of acute myeloid leukemia (AML) within six months from a diagnosis of breast cancer (BC) is rarely reported in the literature, and it is…”
Get full text

“Zeus” a new oral anticoagulant therapy dosing algorithm : A cohort study by Cafolla, A, Melizzi, R, Baldacci, E, Pignoloni, P, Dragoni, F, Campanelli, M, Caraccini, R, Foà, R

“…Abstract The demand for oral anticoagulant therapy (OAT) has constantly increased during the last ten years with an extended use of computer assistance. Many…”
Get full text

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study by Iurlo, A, Cattaneo, D, Consonni, D, Castagnetti, F, Miggiano, M C, Binotto, G, Bonifacio, M, Rege-Cambrin, G, Tiribelli, M, Lunghi, F, Gozzini, A, Pregno, P, Abruzzese, E, Capodanno, I, Bucelli, C, Pizzuti, M, Artuso, S, Iezza, M, Scalzulli, E, La Barba, G, Maggi, A, Russo, S, Elena, C, Scortechini, A R, Tafuri, A, Latagliata, R, Caocci, G, Bocchia, M, Galimberti, S, Luciano, L, Fava, C, Foà, R, Saglio, G, Rosti, G, Breccia, M

“…TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose…”
Get full text